Patent details

EP2712617 Title: Treatment of fibrosis using Fxr ligands

Basic Information

Publication number:
EP2712617
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP131895534
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Treatment of fibrosis using Fxr ligands
French Title of Invention:
Traitement De La Fibrose Au Moyen De Ligands De Fxr
German Title of Invention:
Behandlung Von Fibrose Mit Fxr-Liganden
SPC Number:

Dates

Filing date:
14/03/2005
Grant date:
02/11/2016
EP Publication Date:
02/04/2014
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
02/04/2014
EP B1 Publication Date:
02/11/2016
EP B2 Publication Date:
18/11/2020
EP B3 Publication Date:
Lapsed date:
14/03/2022
Expiration date:
14/03/2025
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
11/11/2020
 
 

Name:
Intercept Pharmaceuticals, Inc.
Address:
421 Hudson Street, Suite 212, New York, NY 10014, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
11/01/2017
Address:
PO Box 48, 8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
Pruzanski, Mark
Address:
United States (US)

2

Name:
Pelliciari, Roberto
Address:
Italy (IT)

3

Name:
Fiorucci, Stefano
Address:
Italy (IT)

Priority

Priority Number:
552865 P
Priority Date:
12/03/2004
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/56;

Publication

European Patent Bulletin

Issue number:
202047
Publication date:
18/11/2020
Description:
Patent maintained (B2 publication)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
29/03/2021
Last Annual Fee Paid Number:
17
Last Annual Fee Paid Amount:
246 Euro
Payer:
Computer Packages INC
Filing date Document type Number of pages
11/01/2017 Incoming Correspondence (Post) 1